Anavex gains as trial for Rett syndrome candidate exceeds enrollment target
Seeking Alpha · 1d ago
BRIEF-Anavex Life Sciences Exceeds Enrollment Target For ANAVEX2-73 EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Reuters · 1d ago
Anavex Life Sciences Completes Enrollment in Phase 2/3 Trial of Potential Rett Syndrome Drug
Anavex Life Sciences Completes Enrollment in Phase 2/3 Trial of Potential Rett Syndrome Drug
MT Newswires · 1d ago
Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved
Seeking Alpha · 4d ago
Healthcare Outlook 2023
Seeking Alpha · 01/23 15:02
Anavex: Drug Treatments For Early Alzheimer's Disease
Seeking Alpha · 01/17 22:10
Anavex: Despite Positive Spin, No Clarity On Anomalies
Seeking Alpha · 01/12 15:49
Lilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approval
Seeking Alpha · 01/06 20:19
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Benzinga · 01/03 13:53
XPEV, LI and BILI are among pre market gainers
Seeking Alpha · 01/03 13:37
Anavex Life Sciences (AVXL) Receives a Buy from H.C. Wainwright
TipRanks · 01/03 11:15
HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Raises Price Target to $50
Benzinga · 01/03 11:13
--HC Wainwright Raises Price Target on Anavex to $50 From $42, Maintains Buy Rating
--HC Wainwright Raises Price Target on Anavex to $50 From $42, Maintains Buy Rating
MT Newswires · 01/03 08:19
Eisai And Biogen's Lecanemab: A Flawed Treatment For Alzheimer's Disease
Seekingalpha · 12/30/2022 22:22
Biogen's Alzheimer's Drug Likely To Be Approved With Warning Labels
Seekingalpha · 12/29/2022 18:41
Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today
Benzinga · 12/27/2022 18:02
Analyzing Anavex Life Sciences's Short Interest
Benzinga · 12/21/2022 21:13
BRIEF-Anavex Strengthens Scientific Advisory Board With Investigator From Phase 2B/3 Alzheimer’S Trial
Reuters · 12/14/2022 12:13
Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years
Benzinga · 12/08/2022 14:31
Cantor Fitzgerald Downgrades Anavex Life Sciences to Neutral, Lowers Price Target to $11
Benzinga · 12/06/2022 13:17
Webull provides a variety of real-time AVXL stock news. You can receive the latest news about Anavex Life Scie through multiple platforms. This information may help you make smarter investment decisions.
About AVXL
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders. The Company’s lead compound ANAVEX2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). Its product candidates also include ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist. ANAVEX 1066, a mixed sigma-1/sigma-2 ligand, is designed for the potential treatment of neuropathic and visceral pain. ANAVEX 1037 is designed for the treatment of prostate and pancreatic cancer.